Sirolimus as combination rescue therapy with tumor necrosis alpha inhibitors for severe, refractory hidradenitis suppurativa - 10/10/20
Funding sources: None. |
|
Disclosure: Dr Bachelez has served on the advisory boards of AbbVie, Almirall, Amgen, Baxalta, Biocad, Boehringer Ingelheim, Celgene, Dermavant, Eli Lilly, Leo Pharma, Janssen, Mylan, Novartis, Pfizer, Sun Pharmaceuticals, and UCB; has served as a speaker for AbbVie, Boehringer Ingelheim, Celgene, Eli Lilly, Leo Pharma, Janssen, Novartis, Pfizer, and UCB; has served as a consultant for AbbVie, Almirall, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen, Kyowa-Kirin, Leo Pharma, Novartis, Pfizer, and UCB; and has received grant support from Boehringer Ingelheim, Leo Pharma, and Pfizer. Drs Bettuzzi, Frumholtz, Jachiet, and Lepelletier, Author Djermane, and Drs Cordoliani, Saussine, and Bouaziz have no conflicts of interest to declare. |
|
IRB approval status: This study was conducted in compliance with the Good Clinical Practice protocol and the Declaration of Helsinki principles and was approved by local ethics committee, who waived the requirement for informed consent (authorisation number: 20190923104020). |
|
Reprints not available from the authors. |
Vol 83 - N° 5
P. 1441-1444 - novembre 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?